Cardiac sympathetic reserve and response to cardiac resynchronization therapy

Circulation: Heart Failure

Volumn 4, Issue 3, 2011, Pages 339-344

  Cha, Yong Mei ^a   Chareonthaitawee, Panithaya ^a   Dong, Ying Xue ^b   Kemp, Bradley J ^a   Oh, Jae K ^a   Miyazaki, Chinami ^a   Hayes, David L ^a   Rea, Robert F ^a   Asirvatham, Samuel J ^a   Webster, Tracy L ^a   Dalzell, Connie M ^a   Hodge, David O ^a   Herges, Regina M ^a   Yong, Yan Zhong ^b   Zhang, Yanhua ^c   Chen, Peng Sheng ^c  

^a MAYO CLINIC   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac resynchronization therapy; Heart failure; Metaiodobenzylguanidine iodine 123; Nerve growth factor; Sympathetic nerve

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BIOLOGICAL MARKER; IODINE 123; NERVE GROWTH FACTOR;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HUMAN; MALE; MEDIASTINUM; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; ADRENERGIC SYSTEM; AGED; BLOOD; CLINICAL TRIAL; INNERVATION; MIDDLE AGED; PATHOPHYSIOLOGY; SCINTISCANNING;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; SYMPATHETIC NERVOUS SYSTEM;

EID: 79960611604     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.959858     Document Type: Article

References (31)

1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350: 2140-2150.
2. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. (Pubitemid 40517094)
3. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the Miracle ICD trial. JAMA. 2003;289:2685-2694. (Pubitemid 37430139)
4. Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy: current and future perspectives. J Cardiovasc Electrophysiol. 2005;16:1117-1124.
5. Breithardt OA, Stellbrink C, Herbots L, Claus P, Sinha AM, Bijnens B, Hanrath P, Sutherland GR. Cardiac resynchronization therapy can reverse abnormal myocardial strain distribution in patients with heart failure and left bundle branch block. J Am Coll Cardiol. 2003;42:486-494. (Pubitemid 36951717)
6. Bleeker GB, Mollema SA, Holman ER, Van de Veire N, Ypenburg C, Boersma E, van der Wall EE, Schalij MJ, Bax JJ. Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation. 2007;116:1440-1448. (Pubitemid 47480634)
7. Liang C, Fan T, Sullebarger J, Sakamotor S. A chamber-specific contributor to beta-adrenoceptor down regulation. J Clin Invest. 1989;84: 1267-1275.
8. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang CS. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation. 1993;88:1299-1309. (Pubitemid 23264051)
9. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci. 1996;19:289-317. (Pubitemid 26080831)
10. Kaye DM, Vaddadi G, Gruskin SL, Du X-J, Esler MD. Reduced myocardial nerve growth factor expression in human and experimental heart failure. Circ Res. 2000;86:e80-e84.
11. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and withinsubject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126-133. (Pubitemid 38949906)
12. Manrique A, Bernard M, Hitzel A, Bauer F, Ménard J-F, Sabatier R, Jacobson A, Véra P, Agostini D. Prognostic value of sympathetic innervation and cardiac asynchrony in dilated cardiomyopathy. Eur J Nucl Med Mol Imaging. 2008;35:2074-2081.
13. Kioka H, Yamada T, Mine T, Morita T, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Hori M, Fukunami M. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213-1218. (Pubitemid 47492905)
14. Yu CM, Gorcsan J III, Bleeker GB, Zhang Q, Schalij MJ, Suffoletto MS, Fung JW, Schwartzman D, Chan YS, Tanabe M, Bax JJ. Usefulness of tissue Doppler velocity and strain dyssynchrony for predicting left ventricular reverse remodeling response after cardiac resynchronization therapy. Am J Cardiol. 2007;100:1263-1270. (Pubitemid 47498285)
15. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J III, St John Sutton M, De Sutter J, Murillo J. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-2616.
16. Bax JJ, Bleeker GB, Marwick TH, Molhoek SG, Boersma E, Steendijk P, van der Wall EE, Schalij MJ. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2004;44:1834-1840. (Pubitemid 39424084)
17. Alonso C, Ritter P, Leclercq C, Mabo P, Bailleul C, Daubert JC. Effects of cardiac resynchronization therapy on heart rate variability in patients with chronic systolic heart failure and intraventricular conduction delay. Am J Cardiol. 2003;91:1144-1147. (Pubitemid 36514941)
18. Najem B, Unger P, Preumont N, Jansens JL, Houssiere A, Pathak A, Xhaet O, Gabriel L, Friart A, De Roy L, Vandenbossche JL, van de Borne P. Sympathetic control after cardiac resynchronization therapy: responders versus nonresponders. Am J Physiol Heart Circ Physiol. 2006;291:H2647-H2652. (Pubitemid 44904063)
19. Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation. 2003;108:266-269. (Pubitemid 36899014)
20. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Circulation. 1998;98:1510-1516. (Pubitemid 28481667)
21. Kawai H, Fan TH, Dong E, Siddiqui RA, Yatani A, Stevens SY, Liang CS. Ace inhibition improves cardiac ne uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. Am J Physiol. 1999;277: H1609-H1617. (Pubitemid 29522695)
22. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, Asai M, Makino N, Kioka H, Kusuoka H, Hori M, Hoki N. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231-238. (Pubitemid 36092191)
23. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, Fukuyama T. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol. 1995;26:1594-1599.
24. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, Hirata A, Asai M, Kusuoka H, Hori M, Hoki N. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656-660. (Pubitemid 33086883)
25. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA, Leon AR, Oshinski JN. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation. 2010;121:1985-1991.
26. Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Van Eck-Smit BL, De Bruin R, Bax JJ, Schalij MJ, Wilde AA, Tukkie R. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol. 2005;28:304-310. (Pubitemid 40613059)
27. Nishioka SA, Martinelli Filho M, Brandao SC, Giorgi MC, Vieira ML, Costa R, Mathias W, Meneghetti JC. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123i-mibg myocardial scintigraphy. J Nucl Cardiol. 2007;14:852-859. (Pubitemid 350082581)
28. Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003;91:684-688. (Pubitemid 36287458)
29. Yu CM, Fung JW, Zhang Q, Chan CK, Chan YS, Lin H, Kum LC, Kong SL, Zhang Y, Sanderson JE. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation. 2004;110:66-73. (Pubitemid 38880135)
30. Sogaard P, Egeblad H, Kim WY, Jensen HK, Pedersen AK, Kristensen BO, Mortensen PT. Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol. 2002;40:723-730.
31. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res. 2001;50:409-416. (Pubitemid 32382168)